Stock Analysis on Net

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Eli Lilly & Co., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings and current maturities of long-term debt 6,904,500 2,244,700 661,600 3,100 1,501,100 1,744,600 2,121,800 1,355,900 1,538,300 1,563,000 1,778,500 4,900 8,700 587,500 1,263,800 3,248,000 1,499,300 1,563,100 2,068,600 2,354,900
Accounts payable 2,598,800 2,435,100 2,474,200 2,015,900 1,930,600 1,683,200 1,659,300 1,433,300 1,670,600 1,566,800 1,597,800 1,639,600 1,606,700 1,430,100 1,247,200 1,207,700 1,405,300 1,114,900 1,198,900 1,168,100
Employee compensation 1,650,400 1,233,200 867,700 739,700 1,059,800 984,100 835,800 693,100 958,100 836,600 755,500 649,900 997,200 795,600 673,600 565,800 915,500 704,500 588,200 511,700
Sales rebates and discounts 11,689,000 11,522,300 10,389,900 9,529,500 8,784,100 8,568,400 7,991,400 6,768,700 6,845,800 7,185,600 7,035,800 5,821,400 5,853,000 5,745,200 5,282,200 4,703,900 4,933,600 5,277,000 4,993,700 4,455,700
Dividends payable 1,169,200 1,016,200 1,017,200 882,200 885,500 770,800 770,600 671,500 593,900
Other current liabilities 3,281,300 4,562,900 3,505,400 3,721,800 2,845,400 2,672,500 2,130,100 3,135,000 3,154,400 2,530,000 3,154,800 3,598,400 3,245,400 3,418,500 3,521,700 2,884,800 2,350,000 2,169,100 2,412,100 2,745,700
Current liabilities 27,293,200 21,998,200 18,915,000 16,010,000 17,138,200 15,652,800 15,620,600 13,386,000 15,052,700 13,682,000 15,093,200 11,714,200 12,481,600 11,976,900 11,988,500 12,610,200 11,775,200 10,828,600 11,855,400 11,236,100
Long-term debt, excluding current maturities 18,320,800 17,923,600 18,158,400 18,880,500 14,737,500 14,143,800 14,692,000 15,152,900 15,346,400 15,522,400 14,736,600 16,199,600 16,586,600 16,334,600 15,064,400 13,982,300 13,817,900 13,662,200 13,717,600 13,610,200
Accrued retirement benefits 1,438,800 1,311,900 1,308,800 1,313,000 1,305,100 1,832,500 1,888,600 1,940,300 1,954,100 3,878,800 3,918,500 3,969,800 4,094,500 3,435,500 3,398,600 3,632,000 3,698,200 2,414,200 2,723,400 2,757,600
Long-term income taxes payable 3,849,200 3,468,300 3,330,700 3,842,100 3,709,600 3,641,700 3,557,600 3,978,100 3,920,000 3,768,500 3,738,000 3,917,500 3,837,800 3,392,700 3,377,500 3,621,900 3,607,200 3,526,500 3,485,700 3,760,400
Other noncurrent liabilities 2,240,600 1,906,100 1,951,800 1,822,500 1,824,000 2,024,800 2,645,600 3,000,000 3,378,000 3,381,200 3,659,200 3,937,900 3,807,400 3,810,300 3,866,000 4,059,200 3,688,500 3,999,300 4,027,000 4,077,500
Other liabilities 25,849,400 24,609,900 24,749,700 25,858,100 21,576,200 21,642,800 22,783,800 24,071,300 24,598,500 26,550,900 26,052,300 28,024,800 28,326,300 26,973,100 25,706,500 25,295,400 24,811,800 23,602,200 23,953,700 24,205,700
Total liabilities 53,142,600 46,608,100 43,664,700 41,868,100 38,714,400 37,295,600 38,404,400 37,457,300 39,651,200 40,232,900 41,145,500 39,739,000 40,807,900 38,950,000 37,695,000 37,905,600 36,587,000 34,430,800 35,809,100 35,441,800
Common stock 593,600 593,600 593,600 593,500 594,100 594,100 594,100 594,100 596,300 598,200 598,100 599,700 598,200 598,100 598,100 598,100 598,800 600,400 603,700 607,100
Additional paid-in capital 7,250,400 7,160,000 6,948,600 6,793,100 6,921,400 6,829,000 6,746,000 6,656,300 6,833,400 6,758,000 6,669,200 6,579,200 6,778,500 6,698,800 6,629,400 6,556,100 6,685,300 6,608,700 6,534,500 5,756,600
Retained earnings 10,312,300 10,309,900 10,368,500 10,639,300 10,042,600 10,006,500 8,556,000 9,369,400 8,958,500 9,639,400 8,530,100 9,181,300 7,830,200 7,154,000 6,617,200 5,879,400 4,920,400 4,981,900 4,318,100 4,879,400
Employee benefit trust (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200)
Accumulated other comprehensive loss (4,327,000) (3,784,900) (3,788,700) (3,777,300) (3,844,600) (4,295,800) (4,287,700) (4,225,300) (4,343,100) (6,172,700) (6,287,100) (6,395,600) (6,496,400) (6,555,100) (6,682,900) (6,885,900) (6,523,600) (5,734,500) (5,600,500) (5,687,500)
Cost of common stock in treasury (44,200) (45,000) (45,000) (45,000) (50,500) (50,500) (50,500) (50,500) (52,700) (52,700) (52,700) (52,700) (55,700) (55,700) (55,700) (55,700) (60,800) (60,800) (62,100) (62,100)
Total Eli Lilly and Company shareholders’ equity 10,771,900 11,220,400 11,063,800 11,190,400 10,649,800 10,070,100 8,544,700 9,330,800 8,979,200 7,757,000 6,444,400 6,898,700 5,641,600 4,826,900 4,092,900 3,078,800 2,606,900 3,382,500 2,780,500 2,480,300
Noncontrolling interests 91,800 87,000 85,500 104,500 125,600 95,800 114,500 131,200 175,600 197,100 219,100 200,600 183,600 169,100 179,100 118,400 92,200 79,800 76,800 84,700
Total equity 10,863,700 11,307,400 11,149,300 11,294,900 10,775,400 10,165,900 8,659,200 9,462,000 9,154,800 7,954,100 6,663,500 7,099,300 5,825,200 4,996,000 4,272,000 3,197,200 2,699,100 3,462,300 2,857,300 2,565,000
Total liabilities and equity 64,006,300 57,915,500 54,814,000 53,163,000 49,489,800 47,461,500 47,063,600 46,919,300 48,806,000 48,187,000 47,809,000 46,838,300 46,633,100 43,946,000 41,967,000 41,102,800 39,286,100 37,893,100 38,666,400 38,006,800

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Eli Lilly & Co. current liabilities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Other liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Eli Lilly & Co. other liabilities decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Eli Lilly & Co. total liabilities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total Eli Lilly and Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Eli Lilly & Co. total Eli Lilly and Company shareholders’ equity increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.